Direct oral anticoagulants (DOACs) are increasingly used and are an important cornerstone in antithrombotic therapy. Adverse drug reactions (ADRs) such as bleedings have only partially been investigated during clinical trials. The primary goal was to analyse pharmacovigilance data based on spontaneous reports of gastrointestinal (GI) bleedings with DOACs reported to EudraVigilance. A second goal was to compare GI safety profiles between DOACs based on these signals. All DOAC related GI bleedings mentioned in individual case safety reports (ICSRs) from 2012 till 2017 in the European Economic Area were classified in four GI categories based on the reported site of occurrence of the haemorrhage. Age group and gender of the patient, seriousness and ADR outcome, and the reporter's qualification were assessed per category and per DOAC. Disproportionality analyses were performed to evaluate whether or not the reported ADRs were more prevalent with a given DOAC. ICSRs were bleeding-related in about half of the cases (n = 28,992/53,471). Of these bleedings, >25% was GI-related. Most patients experiencing GI bleedings were between 65 and 85 years old, with no obvious differences between men and women. Stomach, ulcer-related duodenal, and rectal bleedings were the most reported GI bleedings with a fatal outcome in 5.8%, 7.5%, and 9.8% of the cases for rivaroxaban, apixaban, and dabigatran, respectively. The disproportionality data suggest that dabigatran is more frequently involved in GI bleeding events than the other DOACs. DOACs were significantly associated with GI bleedings. Although the data should be interpreted with caution, it seems that dabigatran was associated more often than other DOACs with GI bleedings based on the analysis of spontaneous pharmacovigilance reports.

Centre for Pharmaceutical Research Research Group of Clinical Pharmacology and Clinical Pharmacy Vrije Universiteit Brussel Jette Belgium

Department of Hospital Pharmacy Universitair Ziekenhuis Brussel Jette Belgium

Department of Social and Clinical Pharmacy Faculty of Pharmacy in Hradec Kralove Charles University Hradec Kralove Czech Republic

KAVA Royal Pharmaceutical Society of Antwerp Antwerp Belgium

Zobrazit více v PubMed

Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND (2017) Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology 152(5):1014-1022.e1. https://doi.org/10.1053/j.gastro.2016.12.018 PubMed DOI

Aloysius MM, Perisetti A, Goyal H et al (2021) Direct-acting oral anticoagulants versus warfarin in relation to risk of gastrointestinal bleeding: a systematic review and meta-analysis of randomized controlled trials. Ann Gastroenterol 34(5):651–659. https://doi.org/10.20524/aog.2021.0658

Barnes GD, Lucas E, Alexander GC, Goldberger ZD (2015) National trends in ambulatory oral anticoagulant use. Am J Med 128(12):1300–5.e2. https://doi.org/10.1016/j.amjmed.2015.05.044 PubMed DOI PMC

Barnes GD, Ageno W, Ansell J, Kaatz S (2015) Recommendation on the nomenclature for oral anticoagulants: communication from the SSC of the ISTH. J Thromb Haemost 13(6):1154–6. https://doi.org/10.1111/jth.12969

Chang HY, Zhou M, Tang W, Alexander GC, Singh S (2015) Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ 350:h1585. https://doi.org/10.1136/bmj.h1585

Chugh SS, Havmoeller R, Narayanan K et al (2014) Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 129(8):837–847. https://doi.org/10.1161/CIRCULATIONAHA.113.005119 PubMed DOI

Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139–1151. https://doi.org/10.1056/NEJMoa0905561 PubMed DOI

Fralick M, Colacci M, Schneeweiss S, Huybrechts KF, Lin KJ, Gagne JJ (2020) Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Ann Intern Med 172(7):463–473. https://doi.org/10.7326/M19-2522

Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093–2104. https://doi.org/10.1056/NEJMoa1310907 PubMed DOI

Gorst-Rasmussen A, Lip GY, Bjerregaard Larsen T (2016) Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf 25(11):1236–1244. https://doi.org/10.1002/pds.4034

Graham DJ, Reichman ME, Wernecke M et al (2016) Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med 176(11):1662–1671. https://doi.org/10.1001/jamainternmed.2016.5954

Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981–992. https://doi.org/10.1056/NEJMoa1107039 PubMed DOI

Gu ZC, Wei AH, Zhang C et al (2020) Risk of major gastrointestinal bleeding with new vs conventional oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 18(4):792–799.e61. https://doi.org/10.1016/j.cgh.2019.05.056

Holster IL, Valkhoff VE, Kuipers EJ, Tjwa ETTL (2013) New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. Gastroenterology 145(1):105-112.e15. https://doi.org/10.1053/j.gastro.2013.02.041 PubMed DOI

Lavalle C, Di Lullo L, Bellasi A et al (2020) Adverse drug reactions during real-life use of direct oral anticoagulants in Italy: an update based on data from the Italian National Pharmacovigilance Network. Cardiorenal Med 10(4):266-276. https://doi.org/10.1159/000507046

Lip GY, Mitchell SA, Liu X et al (2016) Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Int J Cardiol 204:88–94. https://doi.org/10.1016/j.ijcard.2015.11.084 PubMed DOI

Maura G, Billionnet C, Coste J, Weill A, Neumann A, Pariente A (2018) Non-bleeding adverse events with the use of direct oral anticoagulants: a sequence symmetry analysis. Drug Saf 41(9):881–897. https://doi.org/10.1007/s40264-018-0668-9 PubMed DOI PMC

Monaco L, Biagi C, Conti V et al (2017) Safety profile of the direct oral anticoagulants: an analysis of the WHO database of adverse drug reactions. Br J Clin Pharmacol 83(7):1532–1543. https://doi.org/10.1111/bcp.13234 PubMed DOI PMC

Morimoto T, Crawford B, Wada K, Ueda S (2015) Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: a network meta-analysis with the adjustment for the possible bias from open label studies. J Cardiol 66(6):466-74. https://doi.org/10.1016/j.jjcc.2015.05.018

Moudallel S, Steurbaut S, Cornu P, Dupont A (2018) Appropriateness of DOAC prescribing before and during hospital admission and analysis of determinants for inappropriate prescribing. Front Pharmacol 9:1220. https://doi.org/10.3389/fphar.2018.01220 PubMed DOI PMC

Moudallel S, Cornu P, Dupont A, Steurbaut S (2021) Determinants for under- and overdosing of direct oral anticoagulants and physicians’ implementation of clinical pharmacists’ recommendations. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.15017

Patel MR, Mahaffey KW, Garg J et al (2011) Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365(10):883-91. https://doi.org/10.1056/NEJMoa1009638

Piccini JP, Garg J, Patel MR et al (2014) Management of major bleeding events in patients treated with rivaroxaban vs. warfarin: results from the ROCKET AF trial. Eur Heart J 35(28):1873–80. https://doi.org/10.1093/eurheartj/ehu083

Postigo R, Brosch S, Slattery J et al (2018) Eudravigilance medicines safety database: publicly accessible data for research and public health protection. Drug Saf 41(7):665–675. https://doi.org/10.1007/s40264-018-0647-1 PubMed DOI PMC

Radadiya D, Devani K, Brahmbhatt B, Reddy C (2021) Major gastrointestinal bleeding risk with direct oral anticoagulants: does type and dose matter? - a systematic review and network meta-analysis. Eur J Gastroenterol Hepatol. https://doi.org/10.1097/MEG.0000000000002035

Rahman F, Kwan GF, Benjamin EJ (2014) Global epidemiology of atrial fibrillation. Nat Rev Cardiol 11(11):639–654. https://doi.org/10.1038/nrcardio.2014.118 PubMed DOI

Reumerman M, Tichelaar J, Piersma B, Richir MC, van Agtmael MA (2018) Urgent need to modernize pharmacovigilance education in healthcare curricula: review of the literature. Eur J Clin Pharmacol 74(10):1235–1248. https://doi.org/10.1007/s00228-018-2500-y PubMed DOI PMC

Ribeiro-Vaz I, Silva AM, Costa Santos C, Cruz-Correia R (2016) How to promote adverse drug reaction reports using information systems - a systematic review and meta-analysis. BMC Med Inform Decis Mak 16:27. https://doi.org/10.1186/s12911-016-0265-8

Rong F, Jia B, Huang P, Lynn HS, Zhang W (2015) Safety of the direct-acting anticoagulants in patients with atrial fibrillation: a meta-analysis. Thromb Res 135(6):1117–1123. https://doi.org/10.1016/j.thromres.2015.04.004 PubMed DOI

Ruff CT, Giugliano RP, Braunwald E et al (2014) Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383(9921):955–962. https://doi.org/10.1016/S0140-6736(13)62343-0 PubMed DOI

Steffel J, Collins R, Antz M et al (2021) European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. https://doi.org/10.1093/europace/euab065

Verheugt FW, Granger CB (2015) Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet 386(9990):303–310. https://doi.org/10.1016/S0140-6736(15)60245-8 PubMed DOI